Literature DB >> 15544444

A perspective on the current strategies for the treatment of obesity.

Steven V Joyal1.   

Abstract

The prevalence in obesity has increased dramatically over the past 30 years, more than double in the United States alone. Obesity is associated with an increased risk for type 2 diabetes mellitus, dyslipidemia, hypertension, biliary disease, obstructive sleep apnea, and certain types of cancer. The pathophysiology of obesity is complex, involving behavioral, environmental, and genetic factors. Current treatment options include behavior modification and lifestyle changes which incorporate weight-reducing diets and physical activity, FDA approved long-term anti-obesity pharmacological agents sibutramine and orlistat, non-FDA approved over-the-counter (OTC) supplements and nutriceuticals, and, when appropriate, bariatric surgery. Without adequate prevention and treatment of obesity, government agencies have suggested that the direct and indirect costs associated with obesity may overwhelm the healthcare system. This brief review explores the current data available on treatments for the obese patient including the relative merits of different types of macronutrient composition (e.g., low carbohydrate vs. high carbohydrate diets) of weight-reducing diets, the value of resistance/ strength training in physical activity programs designed for the obese patient, the safety and efficacy associated with OTC supplements and nutriceuticals for weight reduction (e.g., Ephedra, conjugated linoleic acid (CLA), Garcinia cambogia/ hydroxycitric acid (HCA), chromium, pyruvate), the safety and efficacy of FDA-approved long-term obesity treatments sibutramine and orlistat, and bariatric surgery.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15544444     DOI: 10.2174/1568007043336978

Source DB:  PubMed          Journal:  Curr Drug Targets CNS Neurol Disord        ISSN: 1568-007X


  6 in total

Review 1.  Nutrigenomic basis of beneficial effects of chromium(III) on obesity and diabetes.

Authors:  Francis C Lau; Manashi Bagchi; Chandan K Sen; Debasis Bagchi
Journal:  Mol Cell Biochem       Date:  2008-07-18       Impact factor: 3.396

2.  Polygonatum sibiricum F. Delaroche polysaccharide ameliorates HFD‑induced mouse obesity via regulation of lipid metabolism and inflammatory response.

Authors:  Bo Liu; Yuan Tang; Zhenyan Song; Jinwen Ge
Journal:  Mol Med Rep       Date:  2021-05-13       Impact factor: 2.952

Review 3.  Complementary and alternative medicine for the treatment of obesity: a critical review.

Authors:  Alireza Esteghamati; Tina Mazaheri; Mona Vahidi Rad; Sina Noshad
Journal:  Int J Endocrinol Metab       Date:  2015-04-20

4.  Nutrigenomic analysis of diet-gene interactions on functional supplements for weight management.

Authors:  Francis C Lau; Manashi Bagchi; Chandan Sen; Sashwati Roy; Debasis Bagchi
Journal:  Curr Genomics       Date:  2008-06       Impact factor: 2.236

5.  Effect of Gambisan on the Inhibition of Adipogenesis in 3T3-L1 Adipocytes.

Authors:  Jung Won Kang; Dongwoo Nam; Kun Hyung Kim; Jeong-Eun Huh; Jae-Dong Lee
Journal:  Evid Based Complement Alternat Med       Date:  2013-08-20       Impact factor: 2.629

6.  The Protective Effects of Danggui-Baizhu-Tang on High-Fat Diet-Induced Obesity in Mice by Activating Thermogenesis.

Authors:  Lijun Zhao; Xiaoqiang Zhu; Renhuai Cong; Xiangliang Yang; Yanhong Zhu
Journal:  Front Pharmacol       Date:  2018-09-05       Impact factor: 5.810

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.